1. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Issue 11 (November 2021) Authors: Facon, Thierry; Kumar, Shaji K; Plesner, Torben; Orlowski, Robert Z; Moreau, Philippe; Bahlis, Nizar; Basu, Supratik; Nahi, Hareth; Hulin, Cyrille; Quach, Hang; Goldschmidt, Hartmut; O'Dwyer, Michael; Perrot, Aurore; Venner, Christopher P; Weisel, Katja; Mace, Joseph R; Raje, Noopur; Tiab, Mourad... Journal: Lancet oncology Issue: Volume 22:Issue 11(2021) Page Start: 1582 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Subcutaneous daratumumab plus standard treatment regimens in patients with multiple myeloma across lines of therapy (PLEIADES): an open‐label Phase II study. (30th July 2020) Authors: Chari, Ajai; Rodriguez‐Otero, Paula; McCarthy, Helen; Suzuki, Kenshi; Hungria, Vania; Sureda Balari, Anna; Perrot, Aurore; Hulin, Cyrille; Magen, Hila; Iida, Shinsuke; Maisnar, Vladimir; Karlin, Lionel; Pour, Ludek; Parasrampuria, Dolly A.; Masterson, Tara; Kosh, Michele; Yang, Shiyi; Delioukina,... Journal: British journal of haematology Issue: Volume 192:Number 5(2021) Page Start: 869 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗